An­thos' blood thin­ner cuts the risk of bleed­ing amid race to de­vel­op safer an­ti­co­ag­u­lants

PHILADEL­PHIA — An an­ti­co­ag­u­lant from An­thos Ther­a­peu­tics sub­stan­tial­ly cut the risk of bleed­ing com­pared to Xarel­to in a mid-stage safe­ty study.

The An­thos drug is part of an up-and-com­ing class of in­ves­ti­ga­tion­al an­ti­co­ag­u­lants that clin­i­cians and com­pa­nies hope will of­fer pa­tients a bet­ter, safer op­tion for pre­vent­ing stroke and blood clots over cur­rent­ly avail­able pills.

The risk of bleed­ing is one of the most feared ef­fects of cur­rent blood thin­ners, which are pre­scribed for peo­ple af­ter they have had cer­tain surg­eries or for those with atri­al fib­ril­la­tion — an ir­reg­u­lar heart­beat that can lead to stroke.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER